• 1. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187

Recent Advances in the Study of 2-(4-Bromophenoxy)benzoic acid (CAS: 74744-77-7)

2-(4-Bromophenoxy)benzoic acid (CAS: 74744-77-7) is a brominated aromatic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. Recent studies have explored its potential applications in drug development, particularly as a scaffold for designing novel therapeutic agents. This research briefing aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

One of the key areas of interest in recent research is the compound's role as an intermediate in the synthesis of more complex molecules. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that 2-(4-Bromophenoxy)benzoic acid can be efficiently synthesized through a palladium-catalyzed coupling reaction, offering a high yield and excellent purity. This method has been optimized for scalability, making it a viable option for industrial applications.

In terms of biological activity, recent in vitro studies have shown that 2-(4-Bromophenoxy)benzoic acid exhibits moderate inhibitory effects on certain enzymes involved in inflammatory pathways. Specifically, it has been found to inhibit cyclooxygenase-2 (COX-2) with an IC50 value of 15 μM, suggesting potential anti-inflammatory properties. However, further in vivo studies are required to validate these findings and assess the compound's pharmacokinetic profile.

Another promising avenue of research involves the use of 2-(4-Bromophenoxy)benzoic acid as a building block for the development of targeted anticancer agents. A recent preprint on bioRxiv (2024) reported that derivatives of this compound showed selective cytotoxicity against breast cancer cell lines (MCF-7), with minimal effects on normal cells. The researchers attributed this activity to the compound's ability to interfere with mitochondrial function in cancer cells, although the exact mechanism remains under investigation.

Despite these promising findings, challenges remain in the clinical translation of 2-(4-Bromophenoxy)benzoic acid and its derivatives. Issues such as poor solubility and limited bioavailability have been identified as potential barriers to its development as a therapeutic agent. Current research is focused on addressing these limitations through structural modifications and formulation strategies, such as nanoparticle encapsulation.

In conclusion, 2-(4-Bromophenoxy)benzoic acid (CAS: 74744-77-7) represents a versatile compound with significant potential in drug discovery and development. Recent advances in its synthesis and biological evaluation have highlighted its utility as a scaffold for designing novel therapeutics, particularly in the areas of inflammation and oncology. Future research should focus on optimizing its pharmacological properties and exploring its mechanisms of action in greater detail.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)